ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com




1. 4ÔÂ17ÈÕ£¬£¬£¬¸´ºêººÁعÙ΢Ðû²¼ÐÂÎųƣ¬£¬£¬Æä×ÔÖ÷¿ª·¢µÄÁ¢ÒìÐÍ¿¹TIGIT FcÈÚºÏÂѰ×HLX53ÁªºÏHÒ© ººË¹×´?£¨Ë¹Â³Àûµ¥¿¹£¬£¬£¬HLX10£©¼°ºº±´Ì©?£¨±´·¥Öéµ¥¿¹£¬£¬£¬HLX04£©µÄÐÂÒ©ÁÙ´²ÊÔÑéÉêÇë»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾Ö£¨NMPA£©Åú×¼£¬£¬£¬ÓÃÓÚ¾Ö²¿ÍíÆÚ»ò×ªÒÆÐÔ¸Îϸ°û°©µÄÒ»ÏßÖÎÁÆ¡£¡£¡£¡£
2. 4ÔÂ17ÈÕ£¬£¬£¬ÉîÐÅÉúÎïÐû²¼ÆäÔÚÑйãÆ×ÐÂÐ͹Ú×´²¡¶¾£¨COVID£©mRNAÒßÃçIN002.5.1»ñµÃÃÀ¹úʳÎïÒ©Æ·¼àÊÓ¹ÜÀí¾Ö(FDA) ¢òÆÚÁÙ´²ÊÔÑéÅú×¼¡£¡£¡£¡£
3. 4ÔÂ17ÈÕ£¬£¬£¬CDE¹ÙÍø¹«Ê¾£¬£¬£¬Èüŵ·Æ£¨Sanofi£©1ÀàÐÂÒ©frexalimab×¢ÉäÒº»ñµÃÁ½ÏîÁÙ´²ÊÔÑéĬʾÔÊÐí£¬£¬£¬»®·ÖÄ⿪·¢ÖÎÁƳÉÈ˸´·¢ÐͶ෢ÐÔÓ²»¯£¨RMS£©¡¢³ÉÈ˷Ǹ´·¢ÐԼ̷¢Ï£ÍûÐͶ෢ÐÔÓ²»¯£¨nrSPMS£©¡£¡£¡£¡£
4. 4ÔÂ16ÈÕ£¬£¬£¬¿µÕÜÒ©ÒµÐû²¼£¬£¬£¬ÆäÁ×Ëá«¿ÉÌæÄáÈé¸àÒѾÔÚÖйú°ÄÃŵØÇø»ñÅúÉÏÊУ¬£¬£¬ÓÃÓÚÖÎÁÆ12Ëê¼°ÒÔÉÏÇàÉÙÄêºÍ³ÉÈË»¼Õß°éÃæ²¿ÊÜÀ۵ķǽڶÎÐͰ×ñ°·ç¡£¡£¡£¡£¹ûÈ»×ÊÁÏÏÔʾ£¬£¬£¬ÕâÊÇ¿µÕÜÒ©ÒµÓÚ2023Äê12ÔÂ×ÔIncyte¹«Ë¾Òý½øµÄÒ»¿î¾Ö²¿JAKÒÖÖÆ¼Á¡£¡£¡£¡£
1. ¿ËÈÕ£¬£¬£¬ÉϺ£Ê«½¡ÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾Óë°²»Õ°²¿ÆÉúÎ﹤³Ì£¨¼¯ÍÅ£©¹É·ÝÓÐÏÞ¹«Ë¾Ç©ÊðÊÚȨÏàÖúÐÒé¡£¡£¡£¡£Æ¾Ö¤¸ÃÊÚȨÐÒ飬£¬£¬Ê«½¡ÉúÎォÆäADC¼¼Êõƽ̨EZWi-Fit?ÊÚȨ°²¿ÆÉúÎï¾ÙÐÐADC²úÆ·µÄ¿ª·¢¡£¡£¡£¡£ÊÚȨʱ´ú£¬£¬£¬°²¿ÆÉúÎォÈÏÕæËùÑвúÆ·ÔÚ´óÖлªµØÇøµÄÁÙ´²Ç°Ñо¿¡¢ÁÙ´²¿ª·¢ºÍÉÌÒµ»¯Éú²úºÍÏúÊÛ£¬£¬£¬²¢ÏòÊ«½¡ÉúÎïÖ§¸¶È¨Ò渶¿î£¨°üÀ¨Ê׸¶¿îºÍÀï³Ì±®¿î£©¼°Õ¼¾»ÏúÊÛ¶îÒ»¶¨±ÈÀýµÄÏúÊÛÌá³É¡£¡£¡£¡£Ê«½¡ÉúÎï»ñµÃ¸ÃADC²úÆ·µÄÍâÑóÈ¨Òæ¡£¡£¡£¡£
1. 4ÔÂ17ÈÕ£¬£¬£¬±±¾©ÉúÃü¿ÆÑ§Ñо¿ËùÉÛ·å¼°±±¾©ÄÔ¿ÆÑ§ÓëÀàÄÔÑо¿ËùÂÞÃôÃôÅäºÏͨѶÔÚNature ÔÚÏß½ÒÏþÌâΪ¡°Brain endothelial GSDMD activation mediates inflammatory BBB breakdown¡±µÄÑо¿ÂÛÎÄ£¬£¬£¬¸ÃÑо¿°ûÖÊÖ¬¶àÌÇ(LPS)´«¸ÐÆ÷caspase-11¼¤»î³É¿×ÂѰ×GSDMD£¬£¬£¬µ«²»ÊÇͨ¹ýTLR4ÓÕµ¼µÄϸ°ûÒò×Ó£¬£¬£¬ÔÚÑ»·LPS»òLPSÓÕµ¼µÄ°ÜѪ֢Öн鵼ѪÄÔÆÁÕÏÆÊÎö¡£¡£¡£¡£
[1]Wei, C., Jiang, W., Wang, R. et al. Brain endothelial GSDMD activation mediates inflammatory BBB breakdown. Nature (2024). https://doi.org/10.1038/s41586-024-07314-2
Ïà¹ØÐÂÎÅ